On the other hand, in the clinical studies reported by Garon et al. and Schilsky et al., 14.1% and 20.0% of the patients with nonsq NSCLC were EGFR/ALK-mutation-positive, which is similar to the subpopulation rate in the present study (16.6%), so we do not believe that this demonstrates significant selection bias for a clinical benefit. This evidence concerns the gene EGFR and non-small cell lung carcinoma.